Lewis Brisbois Advises Lantern Pharma on $26.25 Million Initial Public Offering
Sacramento, Calif. (June 17, 2020) - A Lewis Brisbois team advised Lantern Pharma Inc. in connection with its initial public offering (IPO). Lantern Pharma sold 1,750,000 shares of its common stock at a public offering price of $15.00 per share. Lantern Pharma has granted the underwriters a 45-day option to purchase up to an additional 262,500 shares of common stock at the IPO price, which would increase the size of the IPO to $30.19 million. The company is now listed as LTRN on the Nasdaq.
Lantern Pharma is a biotechnology company, focused on leveraging artificial intelligence (A.I.), machine learning, and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies. Lantern Pharma has more than 100 patents and applications, including on its RADR® platform.
ThinkEquity, a division of Fordham Financial Management, Inc., acted as sole book-running manager for the offering. Colliers Securities LLC and Paulson Investment Company, LLC acted as co-managers for the offering. Blank Rome acted as counsel for the underwriters.
The Lewis Brisbois team was led by Partner Scott Bartel, and included Partners Daniel B. Eng, Deborah K. Seo, John J. Heber (Benefits), Michael J. Grace (Tax), and Nigamnarayan Acharya (Intellectual Property), and Associate Sheryl Lynn Tan.
For more information on this closing, please contact Mr. Bartel or Mr. Acharya directly.
Sacramento, CA San Francisco, CA Los Angeles, CA